Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

BACKGROUND: Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention. The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodent...

Descripción completa

Detalles Bibliográficos
Autores principales: Klausen, Mette Kruse, Jensen, Mathias Ebbesen, Møller, Marco, Le Dous, Nina, Jensen, Anne-Marie Østergaard, Zeeman, Victoria Alberte, Johannsen, Claas-Frederik, Lee, Alycia, Thomsen, Gerda Krog, Macoveanu, Julian, Fisher, Patrick MacDonald, Gillum, Matthew Paul, Jørgensen, Niklas Rye, Bergmann, Marianne Lerbæk, Enghusen Poulsen, Henrik, Becker, Ulrik, Holst, Jens Juul, Benveniste, Helene, Volkow, Nora D., Vollstädt-Klein, Sabine, Miskowiak, Kamilla Woznica, Ekstrøm, Claus Thorn, Knudsen, Gitte Moos, Vilsbøll, Tina, Fink-Jensen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675448/
https://www.ncbi.nlm.nih.gov/pubmed/36066977
http://dx.doi.org/10.1172/jci.insight.159863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675448/
https://www.ncbi.nlm.nih.gov/pubmed/36066977
http://dx.doi.org/10.1172/jci.insight.159863

Ejemplares similares